A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEFPHN1) (Post Shingles Pain).
Conquest Research needs volunteers for an investigational trial evaluating a medication designed to help treat patients suffering from Postherpetic Neuralgia. You may qualify if you:
Eligible participants will receive study-related care at no cost. Compensation for time and travel may be available. No medical insurance is required for participation.